Ocular Therapeutix (NASDAQ:OCUL) COO Donald Notman Sells 11,446 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 11,446 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $103,471.84. Following the transaction, the chief operating officer directly owned 366,356 shares of the company’s stock, valued at $3,311,858.24. The trade was a 3.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Donald Notman also recently made the following trade(s):

• On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The stock was sold at an average price of $8.54, for a total value of $51,538.90.
• On Monday, February 2nd, Donald Notman sold 5,455 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.14, for a total value of $49,858.70.

Ocular Therapeutix Trading Down 21.3%

Shares of Ocular Therapeutix stock traded down $1.89 during midday trading on Tuesday, reaching $6.99. 51,503,167 shares of the company’s stock traded hands, compared to its average volume of 4,346,415. The stock has a 50 day moving average of $11.22 and a 200-day moving average of $11.78. Ocular Therapeutix, Inc. has a 12 month low of $5.78 and a 12 month high of $16.44. The company has a market cap of $1.52 billion, a PE ratio of -4.85 and a beta of 0.90. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The business had revenue of $13.25 million for the quarter, compared to the consensus estimate of $16.13 million. During the same period in the previous year, the firm earned ($0.29) EPS. The company’s quarterly revenue was down 22.4% compared to the same quarter last year. As a group, equities analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Ocular Therapeutix by 26.3% in the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after buying an additional 2,411,953 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Ocular Therapeutix by 5.1% during the 4th quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company’s stock worth $130,842,000 after acquiring an additional 527,777 shares during the last quarter. TCG Crossover Management LLC grew its position in shares of Ocular Therapeutix by 15.0% during the 3rd quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock valued at $71,510,000 after acquiring an additional 798,084 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of Ocular Therapeutix by 15.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company’s stock worth $56,148,000 after purchasing an additional 620,700 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Ocular Therapeutix by 30.5% in the 4th quarter. Geode Capital Management LLC now owns 4,356,547 shares of the biopharmaceutical company’s stock worth $52,896,000 after purchasing an additional 1,018,094 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a report on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday. Chardan Capital reissued a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 9th. Finally, Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Key Stories Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.